The COST Action proposed by Cardiolinc Board Members Yvan Devaux and Clarissa Pedrosa da C. Gomes and co-proposed by other Cardiolinc members, partners and external collaborators has been approved.
The recently approved COST Action CARDIOPROTECTION will address the challenge to translate new cardioprotective therapies for heart failure discovered in the laboratory setting into the clinical setting.
